Is SYGGF or MRK a better dividend investment in 2026?

SYGGF currently yields 2000000.00% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: SYGGF offers higher current income.

What is the dividend yield difference between SYGGF and MRK?

SYGGF has a forward dividend yield of 2000000.00% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 1999997.24 percentage points.

Home › Compare › SYGGF vs MRK

SYGGF vs MRK: Dividend Comparison 2026

SYGGF yields 2000000.00% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SYGGF wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SYGGF

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full SYGGF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — SYGGF vs MRK

📍 SYGGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SYGGF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SYGGF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SYGGF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYGGF

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, SYGGF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYGGF + MRK for your $10,000?

SYGGF: 50%MRK: 50%

100% MRK50/50100% SYGGF

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SYGGF

Analyst Ratings

Hold

Consensus: Hold

Altman Z

-27.5

Piotroski

1/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYGGF buys

MRK buys

No recent congressional trades found for SYGGF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSYGGFMRK

Forward yield	2000000.00% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$4.879226400974806e+39M	$56.8K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$9,798.13
Total dividends collected	$4.879195005460081e+39M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Hold	Buy

Year-by-year: SYGGF vs MRK ($10,000, DRIP)

Year	SYGGF Portfolio	SYGGF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,206	$366.19	+$200.00M → SYGGF
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,650	$502.35	+$3738731.76M → SYGGF
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$14,407	$694.19	+$65315062866.92M → SYGGF
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$16,585	$967.82	+$1066400830062625.00M → SYGGF
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$19,342	$1,363.89	+$16272182796453826560.00M → SYGGF
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$22,913	$1,947.19	+$2.3205424011366188e+23M → SYGGF
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$27,662	$2,823.89	+$3.0927990661046884e+27M → SYGGF
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,159	$4,173.35	+$3.8524105697352695e+31M → SYGGF
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$43,337	$6,308.80	+$4.484688260147987e+35M → SYGGF
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$56,776	$9,798.13	+$4.879226400974806e+39M → SYGGF

SYGGF vs MRK: Complete Analysis 2026

SYGGF — Stock

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Full SYGGF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this SYGGF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYGGF vs SCHD SYGGF vs JEPI SYGGF vs O SYGGF vs KO SYGGF vs MAIN SYGGF vs JNJ SYGGF vs ABBV SYGGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.